Evidence map›Paper›PMID 33511129›Full record

ArticleFrontiers in cell and developmental biology2020

Modeling Uremic Vasculopathy With Induced Pluripotent Stem Cell-Derived Endothelial Cells as a Drug Screening System.

Hye Ryoun Jang, Hyung Joon Cho, Yang Zhou, Ning-Yi Shao, Kyungho Lee, Hoai Huong Thi Le, Junseok Jeon, Jung Eun Lee, Wooseong Huh, Sang-Ging Ong and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Hye Ryoun JangDivision of Nephrology, Department of Medicine, Samsung Medical Center, Stem Cell & Regenerative Medicine Institute(SCRMI), Sungkyunkwan University School of Medicine, Seoul, South Korea.
Hyung Joon ChoSchool for Engineering of Matter, Transport & Energy, Arizona State University, Tempe, AZ, United States.
Yang ZhouStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, United States.
Ning-Yi ShaoHealth Sciences, University of Macau, Macau, China.
Kyungho LeeDivision of Nephrology, Department of Medicine, Samsung Medical Center, Stem Cell & Regenerative Medicine Institute(SCRMI), Sungkyunkwan University School of Medicine, Seoul, South Korea.
Hoai Huong Thi LeDepartment of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, AZ, United States.
Junseok JeonDivision of Nephrology, Department of Medicine, Samsung Medical Center, Stem Cell & Regenerative Medicine Institute(SCRMI), Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jung Eun LeeDivision of Nephrology, Department of Medicine, Samsung Medical Center, Stem Cell & Regenerative Medicine Institute(SCRMI), Sungkyunkwan University School of Medicine, Seoul, South Korea.
Wooseong HuhDivision of Nephrology, Department of Medicine, Samsung Medical Center, Stem Cell & Regenerative Medicine Institute(SCRMI), Sungkyunkwan University School of Medicine, Seoul, South Korea.
Sang-Ging OngDepartment of Pharmacology & Regenerative Medicine, University of Illinois College of Medicine, Chicago, IL, United States.
Won Hee LeeDepartment of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, AZ, United States.
Yoon-Goo KimDivision of Nephrology, Department of Medicine, Samsung Medical Center, Stem Cell & Regenerative Medicine Institute(SCRMI), Sungkyunkwan University School of Medicine, Seoul, South Korea.
Samsung Medical Center · KRSungkyunkwan University · KRUniversity of Arizona · USArizona State University · USCardiovascular Institute of the South · USUniversity of Illinois Urbana-Champaign · USUniversity of Macau · MO

Funding

Rab GTPases-mediated mitochondrial clearance in diabetic cardiomyopathyR01HL148756 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ONG, SANG GING · 2020 to 2024
$2.4M
CARDIAC MITOHORMESIS PROTECTS AGAINST DIABETIC CARDIOMYOPATHY THROUGH MITOPHAGY: EVALI ADMINISTRATIVE SUPPLEMENTR00HL130416 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ONG, SANG GING · 2018 to 2020
$927k
Cardiac Mitohormesis Protects Against Diabetic Cardiomyopathy Through MitophagyK99HL130416 · NHLBI · STANFORD UNIVERSITY · PI ONG, SANG GING · 2016 to 2017
$258k
NHLBI NIH HHS K99 HL130416NHLBI NIH HHS R00 HL130416NHLBI NIH HHS R01 HL148756
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

chronic kidney diseaseendothelial cellsinduced pluripotent stem cellsuremic toxinuremic vasculopathy

Identifiers

PMID33511129
PMCPMC7835337
OpenAlexW3120281643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.